Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study

2025·

H. Linardou

,

K. Papadopoulou

Nikolaos Korfiatis

,

A. Goussia

,

E. Samantas

,

G. Aravantinos

,

A. Christopoulou

,

N. Spathas

,

E. Fountzilas

,

A. Psyrri

,

G.-A. Koliou

,

S. Meditskou

,

E. Kosmas

,

M. Bobos

,

A.V. Charchanti

,

I. Vamvakaris

,

A. Koumarianou

,

D. Bafaloukos

,

P.A. Kosmidis

,

G. Fountzilas

,

G. Mountzios

NCT03568097 Cite DOI

Journal Article Clinical Trial

Authors

Nikolaos Korfiatis

Professor of Data Management and Analytics

Professor of Data Management and Analytics at the Department of Informatics, Ionian University, Corfu. Senior Statistician of the Hellenic Cooperative Oncology Group (HeCOG).

---

← Frequency of Adverse Events Reported Digitally by Patients with Advanced NSCLC: Analysis From CLIMEDIN, a HeCOG Study 2025

SNF-CLIMEDIN: A HECOG prospective randomized trial of digital support and intervention in patients with advanced NSCLC—Final results 2025 →